The findings identify specific receptors for the neurotransmitter acetylcholine that re-route information flowing through memory circuits in the hippocampus.
Bristol-led research has identified specific drug targets within the neural circuits that encode memories, paving the way for significant advances in the treatment of a broad spectrum of brain disorders.
Loss of memory is a core feature of many neurological and psychiatric disorders including Alzheimer’s disease and schizophrenia. Current treatment options for memory loss are very limited and the search for safe and effective drug therapies has, until now, had limited success.
The research was done in collaboration with colleagues at the international biopharmaceutical company Sosei Heptares. The findings, published in Nature Communications, identify specific receptors for the neurotransmitter acetylcholine that re-route information flowing through memory circuits in the hippocampus. Acetylcholine is released in the brain during learning and is critical for the acquisition of new memories. Until now, the only effective treatment for the symptoms of cognitive or memory impairment seen in diseases such as Alzheimer’s is using drugs that broadly boost acetylcholine. However, this leads to multiple adverse side effects. The discovery of specific receptor targets that have the potential to provide the positive effects whilst avoiding the negative ones is promising.
Lead author, Professor Jack Mellor, from the University of Bristol’s Centre for Synaptic Plasticity, said: “These findings are about the fundamental processes that occur in the brain during the encoding of memory and how they may be regulated by brain state or drugs targeting specific receptor proteins. In the long-term, the discovery of these specific targets opens up avenues and opportunities for the development of new treatments for the symptoms of Alzheimer’s disease and other conditions with prominent cognitive impairments. The academic-industry partnership is important for these discoveries and we hope to continue working together on these projects.”
Dr Miles Congreve, Chief Scientific Officer at Sosei Heptares, added: “These important studies have helped us to design and select new, exquisitely targeted therapeutic agents that mimic the effects of acetylcholine at specific muscarinic receptors, without triggering the unwanted side effects of earlier and less-well targeted treatments. This approach has the exciting potential to improve memory and cognitive function in patients with Alzheimer’s and other neurological diseases.”
“It is fascinating how the brain prioritises different bits of information, working out what is important to encode in memory and what can be discarded. We know there must be mechanisms to pull out the things that are important to us but we know very little about how these processes work. Our future programme of work aims to reveal how the brain does this using acetylcholine in tandem with other neurotransmitters such as dopamine, serotonin and noradrenaline,” said Professor Mellor.
Original Article: Research reveals drug targets for memory enhancement
More from: University of Bristol
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Memory loss treatment
- Review: Savi and the Memory Keeper by Bijal Vachharajanion August 1, 2022 at 9:37 am
In this novel about environmental issues and the healing powers of nature, a teenager coping with great loss finds succour in tending to plants ...
- Sleeping less than 9 hours could affect kids’ memory and mental healthon August 1, 2022 at 6:36 am
Story at a glance University of Maryland researchers examined MRI images and medical records of more than 8,300 children aged 9 to 10. The team linked lack of sleep to mental health issues like ...
- Persistent loss of smell due to COVID-19 may better predict long-term cognitive, functional impairmenton July 31, 2022 at 8:40 pm
New insights into factors that may predict, increase or protect against the impact of COVID-19 and the pandemic on memory and thinking skills were revealed by multiple studies reported today at the ...
- PERSISTENT LOSS OF SMELL DUE TO COVID-19 CLOSELY CONNECTED TO LONG-LASTING COGNITIVE PROBLEMSon July 31, 2022 at 11:53 am
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2022Also, ICU Stay May Double Risk of Dementia in Older Adults SAN DIEGO, July 31, 2022 ...
- Rapid Loss of Smell Predicts Dementia and Smaller Brain Areas Linked to Alzheimer’son July 28, 2022 at 1:41 pm
Smell loss in older individuals not only can predict cognitive decline, but it can also foretell structural changes in brain structures linked to Alzheimer's disease, a new study reports.
Go deeper with Google Headlines on:
Memory loss treatment
Go deeper with Bing News on:
- The Alzheimer’s Association recognizes seven researchers for contributions to the field of dementia scienceon August 1, 2022 at 5:34 am
The Alzheimer’s Association will present seven awards at the Alzheimer’s Association International Conference 2022, recognizing researchers for their varied expertise, noteworthy achievements and ...
- SEVEN RESEARCHERS HONORED FOR SCIENTIFIC ACHIEVEMENTS AND CONTRIBUTIONS TO THE DEMENTIA FIELD AT ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCEon July 31, 2022 at 4:22 pm
"Our understanding of dementia science today owes much to these seven researchers and their collaborators," said Maria C. Carrillo, Ph.D., chief science officer, Alzheimer's Association. "The ...
- Men's Cannabis Use Affects Their Future Kids' Healthon July 29, 2022 at 8:49 am
Decades of research have shown us how mothers’ consumption of marijuana during pregnancy can affect the health and development of their children. Fetal exposure to tetrahydrocannabinol (or THC, the ...
- Cytisine may prove a safe and effective smoking cessation therapyon July 28, 2022 at 8:11 am
Research published in the Journal of Thoracic Oncology shows cytisine may be a safe and effective smoking cessation therapy in lung cancer screening volunteers.
- AstraZeneca : Ultomiris Recommended For Approval In EU For Treatment Of Neuromuscular Diseaseon July 24, 2022 at 11:27 pm
In the trial, Ultomiris was superior to placebo in the primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile total score at Week 26, a patient-reported ...